What is Ultherapy?
Ultherapy operates at the intersection of medical technology and cosmetic dermatology, providing a non-invasive solution for skin lifting and collagen stimulation. Utilizing advanced micro-focused ultrasound energy, the platform offers a precise, FDA-cleared alternative to traditional surgical procedures. The company's core value proposition lies in its real-time imaging capabilities, which allow practitioners to visualize tissue layers during treatment, thereby ensuring optimal energy delivery. As the recognized gold standard for nonsurgical rejuvenation, Ultherapy addresses the growing consumer demand for effective, low-downtime aesthetic interventions that yield natural-looking results for the neck, brow, and submental regions.
How much funding has Ultherapy raised?
Ultherapy has raised a total of $38.5M across 3 funding rounds:
Series B
$22.5M
Series C
$10.5M
Series A
$5.5M
Series B (2008): $22.5M with participation from New Enterprise Associates and 3i Group
Series C (2011): $10.5M led by Apposite Capital and New Enterprise Associates
Series A (2020): $5.5M supported by 3i
Key Investors in Ultherapy
New Enterprise Associates
A prominent global venture capital firm that focuses on helping entrepreneurs build transformative businesses across the healthcare and technology sectors.
3i Group
An international investment manager specializing in private equity and infrastructure, with a strong track record of supporting growth-stage medical and healthcare enterprises.
Apposite Capital
A dedicated healthcare investment firm that provides capital and strategic guidance to companies developing innovative medical technologies and services.
What's next for Ultherapy?
With the support of its latest capital injection, Ultherapy is well-positioned to accelerate its market penetration and refine its technological roadmap. The strategic focus will likely shift toward expanding the clinical applications of its ultrasound platform and enhancing the integration of its imaging software to improve practitioner efficiency. As the aesthetic industry continues to favor minimally invasive procedures, the company is expected to leverage its established brand equity to capture a larger share of the global dermatology market. Future growth initiatives will likely involve scaling distribution networks and investing in longitudinal clinical studies to further validate the longevity and safety of its skin-lifting protocols.
See full Ultherapy company page
